Regier, D.A., Pollard, S., McPhail, M. et al. A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada. npj Precis. Onc. 6, 76 (2022). This important new article from CLEO is hot off the press (October 25, 2022) and was supported in part by ARCC, as well as Genome (more…)

We are happy to announce that CanREValue’s latest publication, Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer, has been accepted for publication in JAMA Oncology. Download a copy of this paper. Abstract IMPORTANCE: The initial assessment of pertuzumab use for treatment of metastatic breast cancer by (more…)

We are excited to share this three-province cost-effectiveness analysis of bevacizumab with first line combination chemotherapy in patients with metastatic colorectal cancer. View the full text at https://journals.sagepub.com/doi/full/10.1177/23814683211021060 Download a PDF copy by Clicking Here Authors: Reka E. Pataky , Jaclyn Beca , David Tran, Wei Fang Dai, Erind Dvorani, (more…)

As part of a broader engagement strategy, the CanREValue Collaboration has launched a stakeholder consultation process. Earlier in 2020, the CanREValue Collaboration undertook public stakeholder consultation regarding the Interim Policy Report developed by the CanREValue Working Groups. From this consultation, we received 21 constructive submissions from a diverse set of (more…)

ARCC and the CanREValue Collaboration are excited to share our recent study, using Ontario based real-world data to generate real-world evidence on the comparative effectiveness of 2nd line ipilimumab. Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada  Dai WF,  Beca JM, Croxford (more…)